Tenaya Therapeutics (TNYA) Projected to Post Earnings on Monday

Tenaya Therapeutics (NASDAQ:TNYA) is expected to be announcing its Q4 2025 results before the market opens on Monday, March 9th. Analysts expect the company to announce earnings of ($0.12) per share for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Monday, March 9, 2026 at 4:00 PM ET.

Tenaya Therapeutics Trading Down 7.8%

NASDAQ TNYA opened at $0.56 on Monday. The company has a market cap of $91.99 million, a P/E ratio of -0.72 and a beta of 3.22. The company has a fifty day simple moving average of $0.72 and a 200 day simple moving average of $1.14. Tenaya Therapeutics has a 12-month low of $0.36 and a 12-month high of $2.35.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on TNYA shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tenaya Therapeutics in a report on Wednesday, January 21st. Morgan Stanley set a $2.00 price target on shares of Tenaya Therapeutics in a research report on Thursday, January 8th. HC Wainwright decreased their price objective on Tenaya Therapeutics from $5.00 to $3.00 and set a “buy” rating for the company in a report on Friday, December 12th. Canaccord Genuity Group lowered their price objective on Tenaya Therapeutics from $6.00 to $5.00 and set a “buy” rating for the company in a research note on Thursday, December 18th. Finally, Chardan Capital dropped their target price on Tenaya Therapeutics from $9.00 to $8.00 and set a “buy” rating on the stock in a report on Friday, December 12th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $4.50.

Insider Buying and Selling at Tenaya Therapeutics

In other news, major shareholder Group Gp Lp Column III sold 4,056,573 shares of the business’s stock in a transaction that occurred on Wednesday, February 11th. The stock was sold at an average price of $0.68, for a total value of $2,758,469.64. Following the transaction, the insider owned 2,348,183 shares in the company, valued at $1,596,764.44. The trade was a 63.34% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last quarter, insiders sold 8,594,047 shares of company stock valued at $5,430,207. 48.65% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Scientech Research LLC bought a new position in Tenaya Therapeutics in the 3rd quarter valued at $27,000. Jefferies Financial Group Inc. purchased a new position in shares of Tenaya Therapeutics in the 3rd quarter worth about $99,000. Comerica Bank bought a new position in Tenaya Therapeutics during the first quarter valued at about $50,000. Corient Private Wealth LLC purchased a new stake in Tenaya Therapeutics during the fourth quarter worth about $72,000. Finally, Cetera Investment Advisers increased its holdings in Tenaya Therapeutics by 107.0% during the fourth quarter. Cetera Investment Advisers now owns 106,425 shares of the company’s stock worth $76,000 after buying an additional 55,000 shares during the last quarter. Hedge funds and other institutional investors own 90.54% of the company’s stock.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of gene therapy solutions for cardiovascular diseases. Leveraging a proprietary adeno‐associated virus (AAV) platform, the company aims to deliver durable, one‐time treatments for patients suffering from genetic cardiomyopathies and other inherited heart disorders. Its research programs center on optimizing vector design, delivery methods and manufacturing processes to enhance tissue specificity and minimize immune responses.

Founded in 2018 and headquartered in San Carlos, California, Tenaya has built a diversified pipeline of product candidates targeting conditions such as hypertrophic cardiomyopathy and other genetically driven forms of heart disease.